Eben Tessari Sells 15,506 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 15,506 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $30.46, for a total value of $472,312.76. Following the completion of the transaction, the chief operating officer now directly owns 72,363 shares in the company, valued at $2,204,176.98. This trade represents a 17.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Eben Tessari also recently made the following trade(s):

• On Wednesday, June 11th, Eben Tessari sold 45,042 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $30.51, for a total value of $1,374,231.42.
• On Monday, June 9th, Eben Tessari sold 10,319 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $30.38, for a total value of $313,491.22.
• On Monday, May 19th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $26.41, for a total transaction of $316,920.00.
• On Monday, April 14th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $20.48, for a total transaction of $245,760.00.

Kiniksa Pharmaceuticals Price Performance

Shares of KNSA traded up $0.05 on Friday, reaching $27.78. The company's stock had a trading volume of 228,912 shares, compared to its average volume of 629,670. The stock's 50 day simple moving average is $24.95 and its two-hundred day simple moving average is $22.13. The stock has a market capitalization of $2.03 billion, a P/E ratio of -198.38 and a beta of 0.06. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $17.38 and a 12-month high of $30.69.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $137.79 million for the quarter, compared to analysts' expectations of $128.35 million. During the same quarter last year, the company posted ($0.25) EPS. The company's revenue was up 72.5% compared to the same quarter last year. Analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of KNSA. Nuveen Asset Management LLC increased its position in Kiniksa Pharmaceuticals by 7.3% in the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after buying an additional 54,361 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Kiniksa Pharmaceuticals by 46.3% during the 4th quarter. Wellington Management Group LLP now owns 69,813 shares of the company's stock valued at $1,381,000 after acquiring an additional 22,096 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Kiniksa Pharmaceuticals by 36.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company's stock worth $2,414,000 after acquiring an additional 32,393 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Kiniksa Pharmaceuticals in the 4th quarter worth approximately $3,955,000. Finally, Globeflex Capital L P raised its stake in Kiniksa Pharmaceuticals by 217.1% during the 4th quarter. Globeflex Capital L P now owns 88,596 shares of the company's stock worth $1,752,000 after acquiring an additional 60,656 shares during the period. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on KNSA shares. Citigroup began coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a "buy" rating and a $40.00 price objective on the stock. Wedbush reiterated an "outperform" rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Jefferies Financial Group increased their price target on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Finally, Wall Street Zen downgraded Kiniksa Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, June 6th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $38.80.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.